Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Concierge MD LA

Two GLP-1 desks, one scoreboard. We put Eden and Concierge MD LA head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 434 · Grade C

Concierge MD LA

Visit Concierge MD LA Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 52 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Concierge MD LA a bad call — it's best for patients in major cities wanting concierge in-home glp-1 access. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
34
Supply Reliability
92
69
Transparency
93
24
Access Breadth
90
56
Clinical Oversight
92
72
Track Record
89
68
EdenBrief Score 91 · 52Concierge MD LA

Price, coverage & the tracker

EdenConcierge MD LA
Brief Score91/100 (A−)52/100 (C)
Semaglutide$239/moFrom $199/mo (plus a separate fee, compounded)
Tirzepatide$349/moFrom $299/mo (plus a separate fee, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Concierge MD LA: New to the tracker on 1 August 2026. The published line reads From $199/mo (plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.